
Positive results announced for COPD therapy
Biopharmaceutical company EpiEndo has completed a Phase IIA clinical trial for its therapy addressing chronic obstructive pulmonary disease (COPD). EpiEndo is developing orally available, non-antibiotic macrolides, or Barriolides, that reduce inflammation while also limiting antimicrobial resistance (AMR). The company’s lead asset is EP395 and it focuses… Read More
